Introduction
Executive Summary
Axial spondyloarthritis: Overview
• Causes
• Mechanism of Action
• Signs and Symptoms
• Diagnosis
• Disease Management
Pipeline Therapeutics
• Comparative Analysis
Therapeutic Assessment
• Assessment by Product Type
• Assessment by Stage and Product Type
• Assessment by Route of Administration
• Assessment by Stage and Route of Administration
• Assessment by Molecule Type
• Assessment by Stage and Molecule Type
Axial spondyloarthritis - DelveInsight's Analytical Perspective
In-depth Commercial Assessment
• Axial spondyloarthritis companies' collaborations, Licensing, Acquisition -Deal Value Trends
Axial spondyloarthritis Collaboration Deals
• Company-Company Collaborations (Licensing / Partnering) Analysis
• Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
• Comparative Analysis
Bimekizumab: UCB Biopharma
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
• Comparative Analysis
Namilumab: Izana Bioscience
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
• Comparative Analysis
KIN-1901: Kinevant Sciences
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..

Inactive Products
• Comparative Analysis
Axial spondyloarthritis Key Companies
Axial spondyloarthritis Key Products
Axial spondyloarthritis- Unmet Needs
Axial spondyloarthritis- Market Drivers and Barriers
Axial spondyloarthritis- Future Perspectives and Conclusion
Axial spondyloarthritis Analyst Views
Axial spondyloarthritis Key Companies
Appendix

List of Tables
Table 1 Total Products for Axial spondyloarthritis
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products

List of Figures
Figure 1 Total Products for Axial spondyloarthritis
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products

Key Companies
• Pfizer
• Mycenax Biotech
• Clover Biopharmaceuticals
• Celltrion
• UCB
• Gilead Sciences
• Amgen
• Genrix (Shanghai) Biopharmaceuticals
• Sun Pharma Global
• Boehringer Ingelheim
• Jiangsu HengRui Medicine
• Izana Bioscience
• 3SBio
• Tasly Pharmaceuticals Inc.
• Suzhou Zelgen Biopharmaceuticals
• Affibody
• Kinevant Sciences
• Qyuns Therapeutics
• Akeso Biopharma
• Jiangsu HengRui Medicine Co., Ltd
• FunPep Co Ltd.
• Luye Pharma Group
• siRNAgen Therapeutics
• Aclaris Therapeutics
• Dice molecules